Labcorp Holdings Inc.

Valuation Analysis

About the Company

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services,

Labcorp Holdings Inc. Stock at a Glance

Labcorp Holdings Inc. (LH) is currently trading at $266.16 with a market capitalization of $21.8B. The trailing P/E ratio stands at 23.57x, with a forward P/E of 13.69x. The 52-week range spans from $241.81 to $293.72; the current price is 9.4% below the yearly high. Year-over-year revenue growth stands at +5.8%. The net profit margin stands at 6.66%.

💰 Dividend

Labcorp Holdings Inc. pays an annual dividend of $2.88 per share, representing a yield of 1.08%. The payout ratio stands at 25.51%.

📊 Analyst Rating

17 analysts rate Labcorp Holdings Inc. (LH) on consensus: Buy. The average price target is $310.12, implying +16.52% from the current price. Analyst price targets range from $270.00 to $340.00.

Labcorp Holdings Inc.: The Investment Case in Detail

Labcorp Holdings Inc. (LH) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 32.9% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. Wall Street consensus sits at Buy with an average price target implying roughly 16.52% upside from current levels — analyst sentiment is firmly constructive.

Valuation in Context

The PEG ratio at 1.13 sits in the reasonable zone — the price tag is roughly aligned with the company's growth profile, neither punishing nor euphoric.

What to Watch Next

• The forward P/E of 13.69x is meaningfully below the trailing 23.57x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to relatively defensive market behavior.

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Labcorp Holdings Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.